Baltrus Victoria sold $30K of OSCR

Baltrus Victoria (Chief Accounting Officer) sold 958 shares of Oscar Health, Inc. (OSCR) at $31.45 on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Baltrus Victoria
Published Sep 8, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Neutral
high confidence
Mentioned
$OSCR
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRNeutralLow
01

Why it matters

The transaction is small relative to total holdings and unlikely to move the stock price.

02

Market read

Limited relevance; primarily of interest to existing shareholders tracking insider activity.

03

What to watch

Potential future 10b5‑1 sales could accumulate; monitor cumulative insider activity.

Relevance 2/10Novelty 3/10Timing: filing today

Background

Form 4 filing discloses a routine insider sale by Oscar Health's CAO under a pre‑arranged plan.

Company-level read

Ticker impact

$OSCRNeutralHigh confidence
Context

Chief Accounting Officer Baltrus Victoria sold 958 shares for $30,129 via a 10b5‑1 plan on 2026‑09‑03.

Expected impact

Minimal impact; likely absorbed without noticeable price movement.

Evidence & confidence

The sale represents less than 0.2% of total shares held and is pre‑arranged, so market reaction is expected to be muted.

Market effects

No material effect on health‑tech sector; typical insider transaction.

None; limited to Oscar Health shareholders.

None; isolated to a single micro‑cap.

Counterpoint

If the insider had a larger stake, the sale could signal concerns, but the size here is negligible.

Key entities

  • Oscar Health, Inc.

    US‑listed health‑tech insurer (ticker OSCR).

  • Baltrus Victoria

    Chief Accounting Officer of Oscar Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$OSCRHighAI 8/10

What Oscar Health (OSCR) Said on Its Q3 Earnings Call

Oscar Health (OSCR) reported Q3 improvements in medical loss ratio (84%) and SG&A expense ratio (14%). The company raised its 2026 outlook, expecting $850M-$950M in earnings from operations and $19B-$19.3B in revenue. Membership grew 27% YoY to 2.7M, but is expected to decline to 2.5M by year-end due to disenrollments. Oscar plans to expand its footprint and products for 2027.

$OSCRMed

Oscar Health Inc (OSCR) Q3 2026 Earnings Call Highlights: Record Profitability, Raised

Oscar Health (OSCR) reported Q3 2026 earnings with record profitability and raised guidance. Membership declined due to CMS reviews, with more disenrollments expected. Q4 SG&A expenses are projected to rise due to seasonal spending. CEO Mark Bertolini and CFO Richard Blackley discussed market share gains, utilization trends, and CMS program integrity initiatives. The company anticipates stable membership and market growth despite competitive pressures and regulatory uncertainties.

$OSCRHighAI 8/10

Oscar Health (OSCR) Q3 2026 Earnings Call Transcript

Oscar Health (OSCR) reported Q3 2026 revenue of $5.1B, up 70% YoY, with membership at 2.7M, up 27% YoY. Net income was $167.3M, reversing a prior-year loss. The company raised full-year guidance for revenue, earnings, and adjusted EBITDA. Management highlighted expansion into new markets, product launches, and operational efficiencies.

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.